Skip to content

Mannkind MNKD Accrued expenses and other liabilities

Accrued expenses and other liabilities at other companies

Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX

Other financials

Income statement

See full
Revenue$90.2M+15.1%
Gross profit$82.7M+10.8%
Operating income-$1.7M-107%
Net income-$16.6M-226%
EPS (diluted)-$0.05-225%

Balance sheet

See full
Cash & equivalents$52.8M+11.7%
Total debt$12.2M-9.4%
Total equity-$59.2M-1.0%
Total assets$744.4M+81.5%

Cash flow

See full
Operating cash flow-$5.4M+15.9%
CapEx$1.9M+470%
Free cash flow-$7.2M-8.0%

Valuation

See full
Market cap$1.19B+3.5%
Enterprise value$1.15B+3.0%
P/E228.5×
P/S3.3×-0.6×

Profitability

See full
Gross margin91.5%-2.6pp
Operating margin23.3%+3.1pp
Net margin9.3%
FCF margin13.8%

Returns & leverage

See full
Return on equity-8.8%
Debt / equity-0.2×
Current ratio1.9×-0.5×

Where this comes from

Reported directly by Mannkind in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Mannkind’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mannkind's accrued expenses and other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mannkind's accrued expenses and other liabilities?
Mannkind (MNKD) reported accrued expenses and other liabilities of -$5.77M in Q1 2026.
How has Mannkind's accrued expenses and other liabilities changed year-over-year?
Mannkind's accrued expenses and other liabilities decreased by 4406.7% year-over-year, from $134K to -$5.77M.
What is the long-term trend for Mannkind's accrued expenses and other liabilities?
Over 2 years (2022 to 2025), Mannkind's accrued expenses and other liabilities has grown at a 112.2% compound annual growth rate (CAGR), from -$723K to $3.26M.